Ozempic vulva refers to vulvar and vaginal changes experienced by some women using Ozempic, a GLP-1 receptor agonist medication mainly prescribed for type 2 diabetes and weight loss. Though not officially recognized as a side effect by the manufacturer Novo Nordisk, medical experts and users have reported three notable impacts on the vulva and vagina associated with Ozempic use:
- Sagging of the outer labia (labia majora) due to rapid weight loss, which leads to loss of fat pads and visible sagging or deflation of vulvar skin.
- Weakness of the vaginal muscles and pelvic floor muscles, potentially causing vaginal laxity, a feeling of looseness during intercourse, and sometimes urinary incontinence or pelvic organ prolapse.
- Vaginal dryness and changes in vaginal health attributed to dehydration from gastrointestinal side effects, altered hormone levels (especially decreased estrogen related to fat loss), and disruptions in vaginal microbiome balance. These changes can cause discomfort, irritation, and an increased risk of vaginal infections.
The rapid and significant weight loss from Ozempic can cause loss of subcutaneous fat and muscle mass in the genital area, leading to these effects. Women with a history of pelvic surgeries or pelvic floor dysfunction may experience more pronounced symptoms and should consult their healthcare provider before using such medications. In summary, "Ozempic vulva" is a colloquial term describing vulvar sagging, muscle weakness, and dryness linked to the weight loss and physiological changes caused by Ozempic use. It can affect sexual function and pelvic health in some women, although these side effects are not common for the majority. Careful medical guidance is advised for those experiencing symptoms or with preexisting pelvic conditions. This phenomenon has gained attention recently due to increasing reports from women using Ozempic and similar medications for weight management.
